Compare Quest Diagnostics Inc (DGX) vs iShares MSCI India ETF (INDA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs iShares MSCI India ETF — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while iShares MSCI India ETF trades at $46.03 (market cap $5.73B). The key difference: Quest Diagnostics Inc is far larger — about 4.4× iShares MSCI India ETF's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while iShares MSCI India ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and iShares MSCI India ETF for 58 Days on average.
| DGX | INDA | |
|---|---|---|
Market Cap | $25.48B | $5.73B |
Volume | 941,866 | 6,797,522 |
Sector | Health | Broad Market / Factor |
52-Week High | $247.45 | $55.29 |
52-Week Low | $173.49 | $45.42 |
Typical Hold Time | 56 Days | 58 Days |
Enterprise Value | $31.23B | — |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.81, up 1.68% today, with a bullish earnings trend after beating EPS estimates for three consecutive quarters. The stock shows a mixed technical picture with a bearish overall signal but trades near key support at $228. Revenue growth accelerated to $11.04B in 2025, and the company maintains solid profitability with a 9.19% net income margin. Recent news highlights growth in consumer testing and a partnership with Apple Health, though Medicare reimbursement cuts pose a headwind.
The outlook is cautiously optimistic, supported by strong fundamentals and a consensus price target of $250 offering 8% upside. Key opportunities include demand for advanced diagnostics and AI adoption, while risks center on regulatory pressure and rising debt levels. Analyst sentiment is mixed with a slight hold bias, reflecting balanced growth prospects against near-term challenges.
INDA trades at $46.03, down 0.2% on the day, with a bearish technical signal driven by moving averages and oscillators. Key financial ratios are unavailable in the provided data, limiting fundamental assessment. Recent news highlights India's economic growth amid sector-specific challenges, including energy security concerns and pharmaceutical export hurdles, which may influence the ETF's underlying holdings.
The outlook remains cautious due to technical weakness and macroeconomic headwinds in India. Opportunities exist if oversold conditions reverse, but risks include regulatory tensions and sector volatility. Investors should await updated financials for a clearer fundamental picture.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About iShares MSCI India ETF
INDA tracks the MSCI India Index, providing broad exposure to large and mid-cap companies in the Indian stock market. It is structurally dominated by the financials, information technology, and energy sectors, serving as a core instrument for investors seeking a single-country view of India's long-term economic growth.
Read more on INDA →
